Tailoring access to high cost, genetically targeted drugs.
Where this comes from
- Record sourced from PubMed, PMID 15963014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Assessment of real cost effectiveness, with data linked to individual health outcomes while protecting patient privacy, is an essential challenge we need to meet.